225 related articles for article (PubMed ID: 15521997)
1. In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus.
Ganesan LT; Manavathu EK; Cutright JL; Alangaden GJ; Chandrasekar PH
Clin Microbiol Infect; 2004 Nov; 10(11):961-6. PubMed ID: 15521997
[TBL] [Abstract][Full Text] [Related]
2. Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus.
Manavathu EK; Alangaden GJ; Chandrasekar PH
J Antimicrob Chemother; 2003 Jun; 51(6):1423-5. PubMed ID: 12716776
[TBL] [Abstract][Full Text] [Related]
3. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.
Cuenca-Estrella M; Gomez-Lopez A; Garcia-Effron G; Alcazar-Fuoli L; Mellado E; Buitrago MJ; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2005 Mar; 49(3):1232-5. PubMed ID: 15728937
[TBL] [Abstract][Full Text] [Related]
4. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
Espinel-Ingroff A
Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
[TBL] [Abstract][Full Text] [Related]
5. The strength of synergistic interaction between posaconazole and caspofungin depends on the underlying azole resistance mechanism of Aspergillus fumigatus.
Mavridou E; Meletiadis J; Rijs A; Mouton JW; Verweij PE
Antimicrob Agents Chemother; 2015 Mar; 59(3):1738-44. PubMed ID: 25583716
[TBL] [Abstract][Full Text] [Related]
6. In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus.
Krishnan-Natesan S; Wu W; Chandrasekar PH
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):135-7. PubMed ID: 22608136
[TBL] [Abstract][Full Text] [Related]
7. Modeling the combination of amphotericin B, micafungin, and nikkomycin Z against Aspergillus fumigatus in vitro using a novel response surface paradigm.
Brun YF; Dennis CG; Greco WR; Bernacki RJ; Pera PJ; Bushey JJ; Youn RC; White DB; Segal BH
Antimicrob Agents Chemother; 2007 May; 51(5):1804-12. PubMed ID: 17325217
[TBL] [Abstract][Full Text] [Related]
8. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species.
O'Shaughnessy EM; Meletiadis J; Stergiopoulou T; Demchok JP; Walsh TJ
J Antimicrob Chemother; 2006 Dec; 58(6):1168-76. PubMed ID: 17071635
[TBL] [Abstract][Full Text] [Related]
9. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus.
Chiou CC; Mavrogiorgos N; Tillem E; Hector R; Walsh TJ
Antimicrob Agents Chemother; 2001 Dec; 45(12):3310-21. PubMed ID: 11709302
[TBL] [Abstract][Full Text] [Related]
10. Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms.
Mowat E; Lang S; Williams C; McCulloch E; Jones B; Ramage G
J Antimicrob Chemother; 2008 Dec; 62(6):1281-4. PubMed ID: 18819968
[TBL] [Abstract][Full Text] [Related]
11. Antifungal activity against Candida albicans of nikkomycin Z in combination with caspofungin, voriconazole or amphotericin B.
Sandovsky-Losica H; Shwartzman R; Lahat Y; Segal E
J Antimicrob Chemother; 2008 Sep; 62(3):635-7. PubMed ID: 18490373
[No Abstract] [Full Text] [Related]
12. Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.
Meletiadis J; Stergiopoulou T; O'Shaughnessy EM; Peter J; Walsh TJ
Antimicrob Agents Chemother; 2007 Jun; 51(6):2053-64. PubMed ID: 17387150
[TBL] [Abstract][Full Text] [Related]
13. The evaluation of in vitro pharmacodynamic properties of amphotericin B, voriconazole and caspofungin against A. fumigatus isolates by the conventional and colorimetric time-kill assays.
Kiraz N; Oz Y; Dag I
Med Mycol; 2011 Aug; 49(6):594-601. PubMed ID: 21299374
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans.
Manavathu EK; Ramesh MS; Baskaran I; Ganesan LT; Chandrasekar PH
J Antimicrob Chemother; 2004 Feb; 53(2):386-9. PubMed ID: 14729762
[TBL] [Abstract][Full Text] [Related]
15. Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions.
Elefanti A; Mouton JW; Verweij PE; Tsakris A; Zerva L; Meletiadis J
Antimicrob Agents Chemother; 2013 Oct; 57(10):4656-63. PubMed ID: 23856768
[TBL] [Abstract][Full Text] [Related]
16. Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus.
Steinbach WJ; Cramer RA; Perfect BZ; Henn C; Nielsen K; Heitman J; Perfect JR
Antimicrob Agents Chemother; 2007 Aug; 51(8):2979-81. PubMed ID: 17502415
[TBL] [Abstract][Full Text] [Related]
17. Fluvastatin potentiates the activity of caspofungin against Aspergillus fumigatus in vitro.
Natesan SK; Chandrasekar PH; Alangaden GJ; Manavathu EK
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):369-73. PubMed ID: 18061388
[TBL] [Abstract][Full Text] [Related]
18. Reshuffling of Aspergillus fumigatus cell wall components chitin and β-glucan under the influence of caspofungin or nikkomycin Z alone or in combination.
Verwer PE; van Duijn ML; Tavakol M; Bakker-Woudenberg IA; van de Sande WW
Antimicrob Agents Chemother; 2012 Mar; 56(3):1595-8. PubMed ID: 22203603
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus.
Krishnan S; Manavathu EK; Chandrasekar PH
J Antimicrob Chemother; 2005 Jun; 55(6):914-20. PubMed ID: 15824093
[TBL] [Abstract][Full Text] [Related]
20. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.
Steinbach WJ; Singh N; Miller JL; Benjamin DK; Schell WA; Heitman J; Perfect JR
Antimicrob Agents Chemother; 2004 Dec; 48(12):4922-5. PubMed ID: 15561883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
